New oral anticoagulants: Are coagulation units still required?

Thrombosis Journal

Volumn 12, Issue 1, 2014, Pages

  Altman, Raul ^a  

^a Centro de Trombosis Buenos Aires   (Argentina)

Author keywords

Bleeding; Laboratory control; New oral anticoagulant; NOAC

Indexed keywords

EID: 84894062142     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-12-3     Document Type: Review

References (45)

1. Gomes T, Mamdani MM, Holbrook AM, Paterson JM, Hellings C, Juurlink DN. Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ 2013, 185:E121-E127. 10.1503/cmaj.121218, 3563912, 23184840.
2. Reussi C, Schiavi JE, Altman R, Yussem EE, Rouvier J. Unusual complications in the course of anticoagulant therapy. Am J Med 1969, 46:460-463. 10.1016/0002-9343(69)90047-3, 5780369.
3. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006, 114:774-782. 10.1161/CIRCULATIONAHA.106.612812, 16908769.
4. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867. 10.7326/0003-4819-146-12-200706190-00007, 17577005.
5. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991, 324:1865-1875. 10.1056/NEJM199106273242606, 1801769.
6. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133(6 Suppl):160S-198S.
7. Eriksson BI, Dahl OE, Büller HR, Hettiarachchi R, Rosencher N, Bravo ML, et al. BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005, 3:103-111. 10.1111/j.1538-7836.2004.01100.x, 15634273.
8. Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. ODIXa-HIP Study Investigators Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006, 4:121-128.
9. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009, 374:29-38. 10.1016/S0140-6736(09)60738-8, 19539361.
10. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010, 104:633-641. 10.1160/TH10-01-0066, 20694273.
11. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151. 10.1056/NEJMoa0905561, 19717844.
12. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891. 10.1056/NEJMoa1009638, 21830957.
13. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. Engl J Med 2011, 365:981-992.
14. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003, 349:1019-1026. 10.1056/NEJMoa022913, 12968085.
15. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996, 335:540-546. 10.1056/NEJM199608223350802, 8678931.
16. Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004, 141:745-752. 10.7326/0003-4819-141-10-200411160-00005, 15545674.
17. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F. The RE-ALIGN Investigators. Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. N Engl J Med 2013, 369:1206-1214. 10.1056/NEJMoa1300615, 23991661.
18. Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010, 170:1433-1441.
19. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005, 143:241-250. 10.7326/0003-4819-143-4-200508160-00005, 16103468.
20. The ACTIVE. Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009, 360:2066-2078.
21. Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA, SPS3 Investigators Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012, 367:817-825. SPS3 Investigators.
22. Serebruany V, Rao SV, Silva MA. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur Heart J 2010, 31:227-235. 10.1093/eurheartj/ehp434, 19854728.
23. Altman R, Rivas AJ, Gonzalez CD. Bleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: rescue of the template bleeding time in a single-center prospective study. Thromb J 2012, 10:3. 10.1186/1477-9560-10-3, 3268105, 22236361.
24. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011, 365:699-708. 10.1056/NEJMoa1105819, 21780946.
25. Dewilde WJ, Oirbans T, Verheugt FWA, Kelder JC, De Smet BJGL, Herrman JP, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013, 381:1107-1115. 10.1016/S0140-6736(12)62177-1, 23415013.
26. Dewilde W, Berg JT. Design and rationale of the WOEST trial: What is the Optimal antiplatelet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST). Am Heart J 2009, 158:713-718. 10.1016/j.ahj.2009.09.001, 19853687.
27. Rossini R, Musumeci G, Lettieri C, Molfese M, Mihalcsik L, Mantovani P, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol 2008, 102:1618-1623. 10.1016/j.amjcard.2008.08.021, 19064015.
28. Komócsi A, Vorobcsuk A, Kehl D, Aradi D. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome. Systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2012, 172:1537-1545. 10.1001/archinternmed.2012.4026, 23007264.
29. Oldgren J, Wallentin L, Alexander JH, James S, Jönelid B, Steg G, et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J 2013, 10.1093/eurheartj/eht049.
30. Ruiz-Nodar JM, Marín F, Roldán V, Valencia J, Manzano-Fernández S, Caballero L, et al. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?. Circ Cardiovasc Interv 2012, 5:459-66. 10.1161/CIRCINTERVENTIONS.112.968792, 22787018.
31. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006, 151:713-9. 10.1016/j.ahj.2005.04.017, 16504638.
32. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010, 138:1093-100. 10.1378/chest.10-0134, 20299623.
33. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J Am Coll Cardiol 2011, 58:395-401. 10.1016/j.jacc.2011.03.031, 3175766, 21757117.
34. Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR (2) HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 2012, 60:861-7. 10.1016/j.jacc.2012.06.019, 22858389.
35. Donzé J, Rodondi N, Waeber G, Monney P, Cornuz J, Aujesky D. Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study. Am J Med 2012, 125:1095-102. 10.1016/j.amjmed.2012.04.005, 22939362.
36. Ansell J. New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation. Circulation 2012, 125:165-70. 10.1161/CIRCULATIONAHA.111.031153, 22215891.
37. Dunlay SM, Eveleth JM, Shah ND, McNallan SM, Roger VL. Medication adherence among community-dwelling patients with heart failure. Mayo Clin Proc 2011, 86:273-81. 10.4065/mcp.2010.0732, 3068886, 21389248.
38. Holmes HM, Luo R, Kuo YF, Baillargeon J, Goodwin JS. Association of potentially inappropriate medication use with patient and prescriber characteristics in Medicare Part D. Pharmacoepidemiol Drug Saf 2013, 22:728-34. 10.1002/pds.3431, 23494811.
39. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000, 97:3473-8. 10.1073/pnas.97.7.3473, 16264, 10716719.
40. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013, 34:2094-106. 10.1093/eurheartj/eht134, 23625209.
41. Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 2010, 64:956-67. 10.1111/j.1742-1241.2009.02286.x, 20584229.
42. Bloemen S, Hemker HC, Al Dieri R. Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation. Haematologica 2013, 98:549-54. 10.3324/haematol.2012.073601, 23100275.
43. Hemker HC, Béguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995, 74:134-8.
44. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008, 359:938-49. 10.1056/NEJMra0801082, 18753650.
45. Altman R. Anithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy. Thromb J 2007, 5:11. 10.1186/1477-9560-5-11, 2040133, 17727726.